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Aim: The aim of this study was to analyze prognostic factors of early-stage squamous cell carcinoma of the vulva.
Methods: A retrospective analysis was conducted on 35 patients who were treated for early-stage squamous cell
carcinoma of the vulva at Sun Yat-sen University Cancer Center from January 1980 to December 2005. The
Statistical Package for Social Science (SPSS) was used to compare the different strategies of operation and to
analyze the prognostic factors.
Results: Thirty-five patients had early-stage squamous cell carcinoma of the vulva. Of these cases, 26 were well
differentiated, seven were moderately differentiated, and two were poorly differentiated. The five-year survival rate
was 77.1%. Five cases were in FIGO stage 1a and 30 cases were in stage 1b; median survival times were 182.3
months and 152.5 months, and the five-year survival rates were 100% and 81.5% (P >0.05), respectively. The
five-year survival of the patients who underwent local excision; radical vulvectomy and en bloc resection of
inguinofemoral lymphadenectomy; orradical vulvectomyen bloc resection of inguinofemoral lymphadenectomy,
and pelvic lymph nodes was 50%, 81.8%, and 83.9%, respectively. For these cases, 74.3% of the tumors were medial
while 25.7% were lateral, and the five-year survival rates of patients according to tumor location were 87.0% and
64.8% (P <0.05), respectively. The inguinal lymph node not increased and active were 16 cases (45.7%), and
increased, active and hard were 17 cases (48.6%), and syncretic were two cases (5.7%), five-year survival rates were
73.3%, 92.9% and 50% (P <0.05), respectively. Of these cases, 74.3% of the tumors were cauliflower-like and 25.7%
were nodular; five-year survival rates by tumor type were 91.3% and 66.7% (P <0.05), respectively.
Conclusions: For patients with early-stage squamous cell carcinoma of the vulva, surgical operation is the primary,
yet the best, treatment. The related prognostic factors were tumor location (lateral/medial), stage, gross
morphology, and clinical state of the inguinal lymph node.
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In primary gynecological malignancies, vulvar carcinoma
is relatively rare, constituting approximately 3% to 5%.
One of the most common types of vulvar carcinoma is
squamous cell carcinoma, which accounts for about 90%
of malignant tumors, whereas melanoma, basal cell carcin-
oma, Pap adenocarcinoma, sarcoma, and Paget’s disease
are much less common [1]. Early vulvar squamous cell
carcinoma has not been taken seriously enough for lack of
obvious symptoms.* Correspondence: zhangyn@sysucc.org.cn
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reproduction in any medium, provided the orOf the 150 patients with confirmed vulvar squamous cell
carcinoma who were treated in our cancer center, 35 cases
(23%) were early carcinoma (stage I). In recent years, many
scholars have advocated for implementing individualized
surgical treatment with different operations according to
the position, depth of invasion and other risk factors in
early vulvar squamous cell carcinoma cases. But identifica-
tion of early incidence is relatively low, fewer cases are
reported, and operation mode and prognostic factors still
incite controversy. This paper sums up the clinical data of
early vulvar squamous cell carcinoma for 20 years with the
objective of evaluating the impact of clinicopathologic
prognostic factors and different surgical methods on early-
stage vulvar squamous cell carcinoma prognosis.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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From January 1980 to December 2005, 35 patients with
early-stage invasive squamous cell carcinoma of the vulva
presented to Sun Yat-sen University Cancer Center, of
which three cases were complicated with hypertension
and diabetes mellitus. In these 35 cases, patient ages ran-
ged from 30 to 79 years old (median 59.2 years). Upon
presentation, patients who complained of vulva pruritus
or neoplasm accounted for 91.4%, their symptoms
appeared a median time of 72.2 months earlier (ranging
from one month to 20 years), and the follow-up time was
3.7 to 297.7 months (median 79.7). Vulvar biopsy con-
firmed white spot lesions for 60% of the cases.Table 1 Univariate analysis of overall survival and progressio
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Radical vulvectomy and en bloc resection of inguinofemoral
lymph nodes
12
Radical vulvectomy and en bloc resection of inguinofemoral
and pelvic lymph nodes
21
FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; PFFor these cases 74.3% of the tumors were medial type
while 25.7% were lateral type. Determination of disease
stage was performed according to the International Fed-
eration of Gynecology and Obstetrics (FIGO) Criteria
2009, of which five cases were in stage 1a and 30 cases
were in stage 1b.
Only one case, with a large vulvar tumor (maximum
diameter of 4 cm) near the urethra, received one cycle
of chemotherapy preoperatively and two cycles post-
operatively; the remaining cases underwent surgical
treatment alone. The number of patients who underwent
local excision; radical vulvectomy and en bloc resection
of inguinofemoral; or radical vulvectomy, en blocn-free survival time
rvival Progression-free survival







































Table 2 Multivariate analysis of overall survival and progression-free survival time
Prognosis Factor B SE Wald df Sig Exp
(B)
95% CI for Exp(B)
Lower Upper
OS Surgical treatment 1.086 0.389 7.787 1 0.005 2.961 1.381 6.349
PFS Surgical treatment 1.279 0.404 10.029 1 0.002 3.593 1.628 7.929
OS, overall survival; PFS, progression-free survival.
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two, 12 and 21 cases, respectively.
Overall survival was registered according to the time
interval from diagnosis to death due to the disease.
Progression-free survival was registered according to
time interval from diagnosis to the inguinal region re-
currence or distant metastasis. The actuarial survival
and the overall survival for patient groups were calcu-
lated using the Kaplan-Meier method, while the differ-
ence in survival was assessed using the log-rank method.
The impact of factors to overall survival was calculated
with the Cox regression model in order to determine
their independent contribution to the risk of death. Cox
regression analysis was conducted in two steps. In the
first step, univariate regression was estimated individu-
ally for each possible prognostic factor. In the second

















Figure 1 Overall survival of early-stage squamous cell carcinoma of t
excision. B stands for radical vulvectomy and en bloc resection of inguinof
resection of inguinofemoral and pelvic lymph nodes.were entered into a forward stepwise selection routine.
Statistical significance in all cases was defined as
P <0.05. The analysis was performed using the Statistical
Packet for Social Sciences (SPSS, version 13.0). (SPSS
Inc, Chicago, IL).
Results
The five-year overall actuarial survival according to stage
was 100% for clinical stage 1a and 81.5% for stage 1b. Of
the 35 cases, the postoperative incision infection rate
was 33.4%; severe complications such as rubber leg were
not observed in the follow-up period. Five patients
(14.3%) had tumor recurrence at 3.7 to 297.7 (median of
79.7) months after surgery. One patient died due to the re-
currence of lung and mediastinal lymph node metastasis.
One patient had a recurrence in the former location of the









he vulva with different surgical treatment. A stands for local
emoral lymph nodes. C stands for radical vulvectomy and en bloc
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cal treatment was given. Surgical dissection of relapsed
inguinofemoral lymph nodes or wide excision of vulvar re-
currence was performed in case of local or regional recur-
rence. The patient with the recurrence near the urethra
was treated with radiotherapy preoperatively; dosages that
were delivered to the vulvar and inguinofemoral area ran-
ged from 50–60 Gy.
All the results concerning the log-rank test for both
overall and disease-free survival rates for the tested poten-
tial prognostic factors are shown in Table 1. Results of
multivariate Cox regression analysis regarding the impact
of factors to overall survival are given in Table 2. Accord-
ing to the univariate analysis, tumor location (lateral/med-
ial), the general tumor type, clinical state of the inguinal
lymph node and surgical procedure significantly
influenced overall survival. These factors were subse-
quently tested on a multivariate model in terms of step-
wise Cox-regression analysis. Thus, significant effect on
overall survival and disease-free survival was due to surgi-
cal procedure (P = 0.005).
Discussion
Primary cancer of the vulva is the most uncommon of
all gynecological malignancies. It frequently occurs as in-
guinal lymph node metastasis and can invade urinary
and reproductive tracts, thereby requiring, radical vul-
















Figure 2 Overall survival of early-stage squamous cell carcinoma of tlymphadenectomy. However, morbidity is impressive,
seriously affecting a patient's quality of life. Early vulvar
cancer confined to the vulva and with no lymph node
metastasis needs much more individualized treatment.
Recent research suggests that tumor stage, size, location,
differentiation, depth of invasion and tumor-free mar-
gins are significant prognostic indicators [2,3]. However,
because vulvar cancer is rare, randomized studies are
also rare, and identification of prognostic factors remains
controversial. Andreasson et al. concluded that age and
tumor differentiation are among the clinical variables
with significant prognostic value [4]. Moreover, Franck-
man et al. and Kosary reported a negative impact of age
on survival [5]. Podratz et al. developed a model con-
taining clinical stage, positive groin nodes and tumor
size but not age as prognostic factors [6]. Boyce et al.
included only the clinical stage [7]. A study by the
Gynecologic Oncology Group (GOG) showed that the
number of positive lymph nodes is the most important
independent prognostic factor [8]. Our research involved
only early vulvar squamous cell carcinoma (35 patients,
all Stage 1 cases). The results showed the median sur-
vival time of the inguinal lymph node not increased and
active were 162.6, and increased, active and hard were
164.0 and syncretic were 58.7 months. Five-year survival
rates were 73.3%, 92.9% and 50% (P <0.05), respectively.
Although clinical examination in judging the inguinal







he vulva with different location.
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better prognosis, suggesting that carcinoma cells caused
a strong immune response in the lymph system, which
can be more effective in killing tumor cells.
In the process of treatment, Taussig (1940) and Way
(1948) presented a standard operation for cancer of the
vulva (that is, vulvar radical resection and inguinal
lymph node dissection), and the five-year survival rate
for patients on whom this procedure is performed is ap-
proximately 70% [1]. Early stage vulvar squamous cell
carcinoma confirmed no inguinal lymph node metastasis
pathologically, but a 11% to 43% probability of lymph
node micrometastasis exists [9]; Gonzalez and Bosquet
reported a retrospective study of 320 patients with vul-
var cancer who had undergone surgery; of all 214 cases
without suspicious inguinal lymph node metastasis, 48
patients (22.4%) exhibited occult lymph node metastases
[10]. In these cases it is necessary to resect the bilateral
inguinal lymph node. Ali Ay Hand also concluded that
the primary operation mode is the most important prog-
nostic factor for patients, yet is also the only independ-
ent factor [11]. In this group of cases, in addition to two
patients with small vulvar lesions that required local ex-
cision, the remaining patients had unilateral or bilateral
inguinal lymph node dissection. The group requiring in-
guinal lymph node dissection comprised 1) nine cases of
lateral-type tumors, 2) six cases of unilateral lymph node
dissection, 3) two cases of small genital lesions that

















Figure 3 Overall survival of early-stage squamous cell carcinoma of texamination and imaging suggestive of swollen contra-
lateral lymph nodes and requiring bilateral lymph node
dissection, and 5) 26 cases of medial type tumors that
required bilateral lymph node dissection. Survival ana-
lysis revealed that surgical approach is an important fac-
tor affecting the prognosis and is also an independent
prognostic factor for overall survival (P = 0.005) and
progression-free survival time (P = 0.002), as shown in
Figure 1. Our study shows the five-year survival of the
patients who underwent wide local excision plus en bloc
resection of inguinofemoral lymphadenectomy, or who
underwent wide local excision plus en bloc resection of
inguinofemoral lymphadenectomy and pelvic lymph
nodes was 81.8% and 83.9% (P >0.05). Therefore pelvic
lymph node dissection does little to help patient survival
and is no longer considered necessary surgery in most
cases. Since FIGO began the new system of stage identi-
fication in 2009, the size of the lesion no longer serves
as the basis of inguinal lymph node excision for early
vulvar cancer; depth of invasion is a better determinant
of the potential for lymph node metastasis [12].
According to our results, the location of the tumor is
one of the important factors in early vulvar squamous
cell carcinoma. The median survival time in medial type
and lateral type of tumor were 172.5 months and 119.2
months; five-year survival rates according to tumor
location were 87.0% and 64.8% (P <0.05) as shown in
Figure 2. Research has reported that medial tumors de-







he vulva with different tumor type.
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concerns all stages of vulvar tumors, whereas our data
involve only the early vulvar squamous cell carcinoma. It
is possible that early cancer without lymph node metas-
tasis progresses slowly but it is also possible that since
medial types are located close to the urethra and vagina,
thereby easily causing symptoms for patients, they can
be identified earlier and with a better prognosis than the
lateral type. This might be worth exploring in future re-
search involving more cases. In our study, we also found
that the gross preoperative morphology type is cauli-
flower-like, a type which has a better prognosis than the
nodular type. The median survival time by morphology
type was 164 months and 86 months with five-year sur-
vival rates of 91.3% and 66.7% (P <0.05), respectively
(Figure 3). Nodular tumors are generally endogenous
growth, exhibit late onset of symptoms, and easily infil-
trate the lymphatic vessels, whereas cauliflower tumors
tend to grow outside and invade the lymph tube later so
the prognosis is better. Research on morphology types are
still relatively lacking, however, and further randomized
studies are needed to confirm these assumptions.
In early stage vulvar carcinoma patients, there is at
trend towards individualized treatment in order to re-
duce morbidity and sequelae following inguinal lymph
node dissection. However, recurrences in the groin are
almost always fatal. A variety of modifications in groin
treatment have been introduced [13]. For patients with a
stage 1a, tumor confined to the vulva with a maximum
diameter of ≤2 cm and an infiltration depth ≤1 mm,
there is no need to excise the inguinal lymph node [14].
Because the risk of lymph node metastasis is negligible
(<1%), a wide local excision can be used. For stage 1b of
a lateral type case, the occurrence of contralateral in-
guinal lymph node metastasis risk is relatively low, and
may therefore require only resection with ipsilateral
lymph node without the contralateral lymph node. Stage
1b medial type or large unilateral lesions (diameter >2 cm)
still require bilateral inguinal lymph node excision.
Homesley [15] reported that if tumor invasive depth was
≤2 mm, ipsilateral inguinal lymph node positive rate was
61.8%, whereas for contralateral lymph nodes without me-
tastasis but with an infiltration depth of 3 to 5 mm,
contralateral lymph node positivity rate was 11.9%, and if
infiltration depth was 6 to 10 mm, contralateral lymph
node positivity rate was 31.8%. Therefore the author
thinks that, on the premise of individual treatment, en
bloc resection of inguinofemoral lymphadenectomy can
reduce recurrence and metastasis rate.
For early cases, the availability of pelvic and inguinal
area radiotherapy instead of en bloc resection of ingui-
nofemoral lymphadenectomy has become a focus of de-
bate. Perez concluded that early stage vulvar carcinoma
treated by radiotherapy alone or with local excision plusadjuvant postoperative radiotherapy, can effectively re-
duce the incidence of complications, whereas efficacy
with traditional surgery showed no difference [16]. A
prospective study by GOG randomly divided patients
with negative lymph nodes into a simple inguinal radio-
therapy group and an inguinal lymph node resection
group. Five out of 27 patients (18.5%) who received pri-
mary groin radiation developed a groin recurrence,
which is an unacceptably high failure rate, and therefore
the trial was closed in advance of its original accrual goal
[17]. In 2002, Van der Velden and Ansink published a
review in which they concluded that primary radiother-
apy to the groin results in less morbidity but also results
in a higher number of groin recurrences compared with
surgery. They suggested that an operation was the pre-
ferred treatment option for early vulvar cancer patients
[18]. But a large sample, single institution experience by
Katz showed the groin recurrence rate after primary
radiotherapy was similar to only superficial inguinal lym-
phadenectomybut in a higher groin recurrence rate
compared with complete inguinal lymphadenectomy
[19]. As a result, a large sample, prospective study is
needed to confirm whether or not inguinal radiation is
safe for early cancer treatment.
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